PubRank

ORAL T-8 Oral Testosterone for Male Hormonal Contraception (Oral T8)

Clinical Trial ID NCT01167829

PubWeight™ 0.78‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01167829

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996 2.30
2 Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000 2.17
3 Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000 1.99
4 Clinical review 85: Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab 1997 1.72
5 Androgens in men--uses and abuses. N Engl J Med 1996 1.66
6 Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study. J Clin Endocrinol Metab 1996 1.57
7 Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997 1.54
8 Estradiol and testosterone secretion by human, simian, and canine testes, in males with hypogonadism and in male pseudohermaphrodites with the feminizing testes syndrome. J Clin Invest 1972 1.23
9 Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod 2008 1.19
10 A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab 2004 1.13
11 Secretion of unconjugated androgens and estrogens by the normal and abnormal human testis before and after human chorionic gonadotropin. J Clin Invest 1974 0.99
12 Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 2002 0.91
13 Children's virilization and the use of a testosterone gel by their fathers. Eur J Pediatr 2005 0.90
14 Androgen replacement and quality of life in patients treated for bilateral testicular cancer. Eur J Cancer 1999 0.87
15 Pharmacokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadism. J Androl 2011 0.78
16 Pharmacokinetics of 2 novel formulations of modified-release oral testosterone alone and with finasteride in normal men with experimental hypogonadism. J Androl 2010 0.78
17 The therapeutic potential of testosterone patches. Expert Opin Investig Drugs 1998 0.77
Next 100